???global.info.a_carregar???
Identificação

Identificação pessoal

Nome completo
Melanie Aguiar

Identificadores de autor

Ciência ID
6D1F-8500-D2D1
Produções

Publicações

Artigo em revista
  1. "Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial". The Lancet Haematology 9 4 (2022): e262-e275. http://dx.doi.org/10.1016/s2352-3026(22)00038-2.
    10.1016/s2352-3026(22)00038-2
  2. Aguiar, Melanie. "First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)". Blood (2019): http://dx.doi.org/10.1182/blood-2019-123374.
    10.1182/blood-2019-123374
  3. Aguiar, Melanie. "Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress". Blood (2019): http://dx.doi.org/10.1182/blood.2019001398.
    10.1182/blood.2019001398
Poster em conferência
  1. Bailey, Katharine; Aref, Sarah; Alapi, Krisztina; Aguiar, Melanie; Dey, Aditi; Burt, Richard; Soowah, Lee; et al. "CD20 Targeting of Oncolytic Measles Virus in the Treatment of Adult Acute Lymphoblastic Leukemia". Trabalho apresentado em American Society of Gene and Cell-Therapy (ASGCT) 21st Annual Meeting, 2018.
  2. Bailey, Katharine; Beaton, Brendan; Kirkwood, Amy; Aguiar, Melanie; Alapi, Krisztina; Clifton-Hadley, Laura; Patrick, Pip; et al. "Re-Thinking The Prognostic Relevance of a CD20 Expression Cut-Off of 20% in Acute Lymphoblastic Leukaemia: Initial Results From The UKALL14 Trial". Trabalho apresentado em 23rd European Hematology Association Congress, 2018.